Anti-diabetic activity glucose metabolizing

Low-grade inflammation is closely associated with the metabolic syndrome and is an accepted new cardiovascular risk factor. Reductions in postprandial glucose excursion by treatment with acarbose in patients with type 2 diabetes have shown to reduce the activity (p = 0.045) and nuclear localization (p = 0.02) of the proinflammatory transcription factor NFkB, suggesting a mechanism by which the anti-inflammatory effects of acarbose may be mediated [8]. This mechanism would be consistent with reductions in the level of coagulation factors seen with acarbose treatment. For example, acarbose has been shown to reduce the level of fibrinogen in patients with type 2 diabetes (p = 0.013 vs. placebo) [42] and serum C-reactive protein levels in individuals with IGT (p < 0.01 vs. placebo) [43]. We found a significant reduction in postprandial leukocyte excursion another indicator... 

---